CLRB Share Price Performance
US$2.76
-6.78 (-71.07%)
96.4% undervalued intrinsic discount
US$76.00
Fair Value
Price US$2.76
AnalystConsensusTarget US$76.00
Fair ValueUS$76.00
Share Pricen/a
Cellectar Biosciences, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
CLRB Community Narratives
AN
Fair Value US$76 96.4% undervalued intrinsic discount
Future Radiopharmaceutical Pipeline Expansion Will Support A Stronger Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Future Radiopharmaceutical Pipeline Expansion Will Support A Stronger Long Term Outlook
Catalysts About Cellectar Biosciences Cellectar Biosciences develops targeted radiopharmaceutical therapies for difficult to treat cancers using its proprietary phospholipid drug conjugate platform. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$76
96.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
10.89%
Future PE
185.57x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Future Radiopharmaceutical Pipeline Expansion Will Support A Stronger Long Term Outlook
Fair Value: US$76 96.4% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cellectar Biosciences, Inc. Key Details
About CLRB
- Founded
- 2002
- Employees
- 11
- CEO
- WebsiteView website
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
